New Delhi, Feb 16 (KNN) In proposed trade agreements, India’s stance on intellectual property rights (IPRs) and pharmaceutical issues strikes a balance between fostering innovation and addressing public health needs, according to a report by the Global Trade Research Initiative (GTRI).
This approach ensures the availability of affordable medicines and supports the growth of the generic medicine industry.
The GTRI paper highlights India’s commitment to balancing innovation with public health needs, adopting a flexible interpretation of Trade-Related Aspects of Intellectual Property Rights (TRIPS) to align with its developmental goals, and preventing the establishment of unfair monopolies, especially in the pharmaceutical sector.